These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3975175)

  • 1. Approaches to prostatic cancer chemotherapy using the Dunning R3327H prostatic adenocarcinoma.
    Padilla GM; Petrow V; Marts SA; Mukherji S
    Prostate; 1985; 6(2):129-43. PubMed ID: 3975175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estramustine binding protein (EMBP) in rat R3327 Dunning tumors: partial characterization and effect of hormonal withdrawal, hormonal replacement, and cytotoxic treatment on its expression.
    Björk P; Isaacs JT; Hartley-Asp B
    Prostate; 1991; 18(3):181-200. PubMed ID: 2020618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach to prostate cancer.
    Ito YZ; Nakazato Y; Petrow V
    J Pharm Pharmacol; 1989 Jul; 41(7):488-9. PubMed ID: 2570857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
    Zaccheo T; Giudici D; di Salle E
    Prostate; 1997 Feb; 30(2):85-91. PubMed ID: 9051146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine potentiates the effects of irradiation on the Dunning (R3327) rat prostatic adenocarcinoma.
    Widmark A; Damber JE; Bergh A; Henriksson R
    Prostate; 1994; 24(2):79-83. PubMed ID: 8309847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal testosterone concentration for the treatment of prostatic cancer.
    Trachtenberg J
    J Urol; 1985 May; 133(5):888-90. PubMed ID: 3989932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of cytotoxic steroids for prostate cancer.
    Petrow V; Padilla GM
    Prostate; 1986; 9(2):169-82. PubMed ID: 3748896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone.
    Petrow V; Padilla GM; Mukherji S; Marts SA
    J Pharm Pharmacol; 1984 May; 36(5):352-3. PubMed ID: 6145781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
    Smolev JK; Heston WD; Scott WW; Coffey DS
    Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
    Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
    Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial characterization and "quantitation" of a human prostatic estramustine-binding protein.
    Björk P; Forsgren B; Gustafsson JA; Pousette A; Högberg B
    Cancer Res; 1982 May; 42(5):1935-42. PubMed ID: 7066904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion.
    English HF; Kloszewski ED; Valentine EG; Santen RJ
    Cancer Res; 1986 Feb; 46(2):839-44. PubMed ID: 3940646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of propagable cell lines (HUNC) from the androgen-sensitive Dunning R3327H rat prostatic adenocarcinoma.
    Presnell SC; Borchert KM; Glover WJ; Gregory CW; Mohler JL; Smith GJ
    Carcinogenesis; 1998 Apr; 19(4):585-90. PubMed ID: 9600341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
    Zaccheo T; Giudici D; di Salle E
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):193-8. PubMed ID: 9605414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of androgen receptor and estramustine binding protein of rat ventral prostatic tissue in organ culture.
    Høisaeter PA; Kadohama N; Corrales JJ; Karr JP; Murphy GP; Sandberg AA
    J Steroid Biochem; 1981 Mar; 14(3):251-60. PubMed ID: 7218791
    [No Abstract]   [Full Text] [Related]  

  • 17. Estramustine binding in rat, baboon and human prostate measured by high pressure liquid chromatography.
    Kirdani RY; Corrales JJ; Høisaeter PA; Karr JP; Murphy GP; Sandberg AA
    Steroids; 1981 May; 37(5):471-84. PubMed ID: 7256814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 6-methylene progesterone on growth, morphology, and blood flow of the Dunning R3327 prostatic adenocarcinoma.
    Damber JE; Bergh A; Daehlin L; Petrow V; Landström M
    Prostate; 1992; 20(3):187-97. PubMed ID: 1574466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melengestrol acetate and megestrol acetate are prostatic tumor inhibiting agents.
    Padilla GM; Yacullo RC; Padilla JJ; Payne B; Petrow V
    Biochem Cell Biol; 1990 Oct; 68(10):1181-8. PubMed ID: 2268413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Dunning tumor growth by melatonin.
    Philo R; Berkowitz AS
    J Urol; 1988 May; 139(5):1099-102. PubMed ID: 3283381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.